| |
Cancer is an incredibly intricate disease. In recent years, there’s been a shift in how early-phase oncology studies are conducted as adaptive trial designs have become more common. These designs aim to increase the chance of trial success. Read our blog to learn more. Premier Research. Built for Biotech℠
|
|
Today's Big NewsFeb 22, 2023 |
|
March 14-15, 2023 | San Francisco, CA Be in the room with the life sciences industry leaders to forge new connections & take advantage of in-person networking opportunities. Find out who you can connect with!
|
|
| By James Waldron Not content with overseeing his ever-expanding ‘vant’ empire, Roivant founder Vivek Ramaswamy has set his sights on a far more ambitious goal: the White House. |
|
|
|
By Gabrielle Masson Moderna has penned a partnership with ElevateBio’s Life Edit Therapeutics in hopes of developing next-gen gene editing therapies for hard-to-treat diseases. |
By Max Bayer Biotechs are pleading for help to develop new treatments for long COVID, as the U.S. moves past the pandemic. Patients and advocates worry they're being left behind. |
Sponsored by Ocugen Ocugen remains diligent in developing innovative COVID-19 vaccine options—including a non-mRNA injectable and next-gen inhaled vaccine—to meet the current need and prepare for an annual booster strategy. |
|
April 3 - 4, 2023 | San Diego, CA The only west coast event exclusively for life science communicators to share best practices, benchmarks, and tools, as well as network with peers. Register by March 10th for the best Rate!
|
|
By Annalee Armstrong It’s the end of the road for Rubius Therapeutics, a biotech that previously wanted to develop cellular therapies for rare diseases, cancer and autoimmune diseases. |
By Nick Paul Taylor Aileron Therapeutics’ unraveling has entered its endgame. An early look at phase 1b data persuaded the biotech to call it quits on development of its sole drug candidate—and lay off most of its remaining staff to hunker down while searching for an exit. |
By Nick Paul Taylor Kinnate Biopharma is going it alone in China. Twenty-one months after setting up a Chinese joint venture with OrbiMed and Foresite Capital Management, the U.S. biotech has bought its partners out for less than it raised in the series A. |
By Annalee Armstrong Amgen is teaming up with the Association of Black Cardiologists and Morehouse School of Medicine to run a study examining cardiovascular risk in African Americans. |
By Angus Liu Hoping to make its long-acting injectable a new standard treatment for HIV, GSK’s ViiV Healthcare has shown that Cabenuva matched Gilead Sciences’ Biktarvy in a head-to-head study. |
By Andrea Park After a tougher-than-expected start to its fiscal year, Medtronic is finally getting back on track. |
By Fraiser Kansteiner Drug manufacturer National Resilience is laying off about 213 employees in Boston, a company spokesperson confirmed via email. The staff reduction is a “function of transition” tied to the end of a manufacturing contract with Sanofi, Resilience chief Rahul Singhvi told Fierce Pharma. |
By Kevin Dunleavy Bayer has big ambitions for its Berkeley campus, where it plans to invest $1.2 billion over the next 30 years. But even a rapidly growing site is not immune to job cuts in today’s belt-tightening environment. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss the intense patent fight between Moderna and Pfizer-BioNTech around the mRNA technology used in their COVID-19 vaccines. We also talk about negotiating vaccine contracts via text messages, one of the biggest medtech deals of the year and other top headlines from this week. |
|
|---|
|
|
| ResearchLike many top 10 and global pharma companies, an H1 client needed to diversify both its patient outreach and site investigator profiles for upcoming trials. Sponsored by: H1 |
| Whitepaper Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies. Sponsored by: Aldevron |
| WhitepaperThis paper explores the cost drivers behind gene therapies and how they are likely to evolve in the coming years. Sponsored by: Blue Matter |
| WhitepaperExploring the biology of G Protein-Coupled Receptors (GPCRs) and outlining a novel approach for developing therapeutics against previously undruggable GPCRs Sponsored by: Orion Biotechnology |
| WhitepaperLearn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| Research Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development. Sponsored by: Catalent |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
